NASDAQ:TTOO - T2 Biosystems Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding T2 Biosystems Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.17 0.00 (0.00 %) (As of 01/26/2020 10:20 AM ET) Add Compare Today's Range$1.11Now: $1.17▼$1.1950-Day Range$0.99MA: $1.15▼$1.2552-Week Range$0.52Now: $1.17▼$5.38Volume580,064 shsAverage Volume574,101 shsMarket Capitalization$54.62 millionP/E RatioN/ADividend YieldN/ABeta1 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TTOO Previous Symbol CUSIPN/A CIK1492674 Webhttp://www.t2biosystems.com/ Phone781-761-4646Debt Debt-to-Equity RatioN/A Current Ratio0.41 Quick Ratio0.34Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10.50 million Price / Sales5.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book4.50Profitability EPS (Most Recent Fiscal Year)($1.26) Net Income$-51,150,000.00 Net Margins-851.71% Return on Equity-1,263.80% Return on Assets-120.66%Miscellaneous Employees153 Outstanding Shares46,680,000Market Cap$54.62 million Next Earnings Date3/5/2020 (Estimated) OptionableOptionable Receive TTOO News and Ratings via Email Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TTOO Rates by TradingView T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions What is T2 Biosystems' stock symbol? T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO." How were T2 Biosystems' earnings last quarter? T2 Biosystems Inc (NASDAQ:TTOO) issued its quarterly earnings data on Monday, November, 18th. The medical equipment provider reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.31). The medical equipment provider earned $1.68 million during the quarter, compared to analyst estimates of $2.17 million. T2 Biosystems had a negative net margin of 851.71% and a negative return on equity of 1,263.80%. View T2 Biosystems' Earnings History. When is T2 Biosystems' next earnings date? T2 Biosystems is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for T2 Biosystems. What guidance has T2 Biosystems issued on next quarter's earnings? T2 Biosystems issued an update on its fourth quarter 2019 After-Hours earnings guidance on Thursday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3-3 million, compared to the consensus revenue estimate of $3.67 million. What price target have analysts set for TTOO? 7 brokerages have issued 1 year target prices for T2 Biosystems' shares. Their forecasts range from $0.40 to $10.00. On average, they expect T2 Biosystems' stock price to reach $5.63 in the next year. This suggests a possible upside of 381.1% from the stock's current price. View Analyst Price Targets for T2 Biosystems. What is the consensus analysts' recommendation for T2 Biosystems? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for T2 Biosystems. What are Wall Street analysts saying about T2 Biosystems stock? Here are some recent quotes from research analysts about T2 Biosystems stock: 1. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (11/15/2019) 2. HC Wainwright analysts commented, "We do not currently have a price target on TTOO shares. Risks include, but are not limited to: (1) failure of to achieve commercial success due to market size, penetration rate, and/or competition; (2) failure to secure regulatory approval for T2Lyme; and (3) potential dilution risk." (8/7/2019) 3. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month PT of $10 on shares of TTOO. T2 reported 1Q19 product revenue of $1.3MM (+25% y/y), beating our estimate and VisibleAlpha consensus estimates by $0.3MM. Total 1Q19 revenue beat FactSet consensus and the top-end of management’s 1Q19 revenue guide. T2 closed on 11 T2Dx contracts during the quarter, above guidance of 8-10. Management reiterated 2019 revenue guidance and provided 2Q product revenue expectations of +35% growth at the midpoint. We are positive on the momentum of T2’s start to the year, and we continue to think that 2H19 will be pivotal for consumable revenue acceleration and consequently the shares." (5/3/2019) Has T2 Biosystems been receiving favorable news coverage? Media headlines about TTOO stock have been trending extremely negative on Sunday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. T2 Biosystems earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for T2 Biosystems. Are investors shorting T2 Biosystems? T2 Biosystems saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 3,540,000 shares, a drop of 17.3% from the December 15th total of 4,280,000 shares. Based on an average daily volume of 608,200 shares, the days-to-cover ratio is presently 5.8 days. Currently, 9.0% of the company's stock are sold short. View T2 Biosystems' Current Options Chain. Who are some of T2 Biosystems' key competitors? Some companies that are related to T2 Biosystems include TELA Bio (TELA), iCAD (ICAD), Venus Concept (VERO), Cytosorbents (CTSO), Liquidia Technologies (LQDA), BRAINSWAY LTD/S (BWAY), Spectral Medical (EDTXF), BeyondAirInc . (XAIR), Neuronetics (STIM), Nephros (NEPH), Nephros (NEPHD), Sensus Healthcare (SRTS), AIT Therapeutics (AITB), Pro-Dex (PDEX) and STRATA Skin Sciences (SSKN). What other stocks do shareholders of T2 Biosystems own? Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Progenics Pharmaceuticals (PGNX), Verastem (VSTM), Exelixis (EXEL), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Zynerba Pharmaceuticals (ZYNE) and Viking Therapeutics (VKTX). Who are T2 Biosystems' key executives? T2 Biosystems' management team includes the folowing people: Mr. John P. McDonough, CEO, Pres & Director (Age 59)Prof. Michael J. Cima, Co-Founder & Director (Age 59)Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 40)Dr. Tyler E. Jacks, Co-Founder (Age 58)Mr. Lee Josephson, Co-Founder & Member of Scientific Advisory Board How do I buy shares of T2 Biosystems? Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is T2 Biosystems' stock price today? One share of TTOO stock can currently be purchased for approximately $1.17. How big of a company is T2 Biosystems? T2 Biosystems has a market capitalization of $54.62 million and generates $10.50 million in revenue each year. The medical equipment provider earns $-51,150,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. T2 Biosystems employs 153 workers across the globe.View Additional Information About T2 Biosystems. What is T2 Biosystems' official website? The official website for T2 Biosystems is http://www.t2biosystems.com/. How can I contact T2 Biosystems? T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected] MarketBeat Community Rating for T2 Biosystems (NASDAQ TTOO)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 346 (Thanks for Voting!)Underperform Votes: 279 (Thanks for Voting!)Total Votes: 625MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe TTOO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTOO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/26/2020 by MarketBeat.com StaffFeatured Article: Price to Earnings Ratio (PE) Basics
